Methodological aspects on hypoxia PET acquisition and image processing

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 3, 2013, Pages 235-243

  Thorwarth, D ^a   Monnich D ^a   Zips, D ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Diagnostic imaging; Hypoxia; Radiotherapy

Indexed keywords

CLINICAL EXAMINATION; HEAD AND NECK CANCER; HUMAN; HYPOXEMIA; HYPOXIA; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; MATHEMATICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TENSION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIGNAL NOISE RATIO; VASCULAR TUMOR;

ANIMALS; CELL HYPOXIA; HUMANS; IMAGE ENHANCEMENT; MOLECULAR IMAGING; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; TUMOR MICROENVIRONMENT;

EID: 84888784274     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9.
2. Nordsmark M, Bentzen SM, Rudat V, Stadler P, Brizel D, Lartigau E et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
3. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiotherapy in patients with locally advanced headand-neck cancer. Radiother Oncol 2012;105:21-8.
4. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20.
5. Horsman M, Mortensen L, Petersen J, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Na Rev Clin Oncol 2012,9:675-87.
6. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60.
7. Höckel M, Schienger K, Aral B, Milze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
8. Gornik G, Weber W. New tracers beyond FDG in head and neck cancer oncology. Q J Nucl Med Mol Imaging 2011;55:529-40.
9. Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging 2012;56:173-90.
10. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011;101:369-75.
11. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S et al. Flourine-18-labeled fluoromisonidazole positron emission tomography and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008;70(1):2-13. (Pubitemid 350251039)
12. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009;50:1020-7.
13. 18F]-Fluoromisonidazole PET predicts treatment outcome in head-and-neck cancer. BMC Cancer 2005;5:152.
14. 18F]-FAZA). Radiat Oncol 2011;6:165.
15. 19F-MRI relaxometry. Radiother Oncol 2012;105:29-35.
16. 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 2012;102:424-8.
17. Bowen S, Chappell R, Bentzen S, Deveau M, Forrest L, Jeraj R. Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. Radiother Oncol 2012;105:41-8.
18. Dubois L, Landuyt W, Cloetens L, Bol A, Bormans G, Haustermans K et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009;36(2):209-18.
19. Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S et al. 18F-EF5: a new tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2009;49:1944-51.
20. Van Loon J, Janssen M, Oilers M, Aerts HJ, Dubois L, Hochstenbag M et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010;37:1663-8.
21. Øvrebø KM, Hompland T, Mathiesen B, Rofstad EK. Assessment of hypoxia and radiation response in intramuscular experimental tumors by dynamic contrast-enhanced magnetic resonance imaging. Radiother Oncol 2012;102:429-35.
22. Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012;72:5285-95.
23. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H et al. Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. Radiother Oncol 2013 [Epub ahead of print].
24. Shi K, Souvatzoglou M, Astner ST, Vaupel P, Nusslin F, Wilkens JJ et al. Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 150-H20 in patients with head and neck tumors. J Nucl Med 2010;51:1386-94.
25. Wang W, Lee NY, Georgi JC, Narayanan M, Guillem J, Schoder H et al. Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med 2010;51:37-45.
26. Jansen JF, Schoder H, Lee NY, Wang Y, Pfister DG, Fury MG et al. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys 2010;77:1403-10.
27. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.
28. Minn H, Suilamo S, Seppala J. Impact of PET/CT on planning of radiotherapy in head and neck cancer. Q J Nucl Med Mol Imaging 2010;54:521-32.
29. Arabi M, Piert M. Hypoxia PET/CT imaging: implications for radiation oncology. Q J Nucl Med Mol Imaging 2010;54:500-9.
30. Thorwarth D, Geets X, Paiusco M. Physical radiotherapy treatment planning based on functional PET/CT data. Radiother Oncol 2010,96:317-24.
31. 18F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 2011;50:22-7.
32. 18F]FMISO tracer dynamics based on tumour tissue microsections. Phys Med Biol 2011;56:2045-57.
33. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300. (Pubitemid 46589864)
34. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur Journal Nucl Med Mol Imaging 2007;34:1566-75. (Pubitemid 47476913)
35. Schuetz M, Schmid MP, Potter R, Kommata S, Georg D, Lukic D et al. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 2010;49-941-7.
36. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol 2009;54:R1-25.
37. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(Suppl 1):11S-20S.
38. Sattler B, Lee JA, Lonsdale M, Coche E. PET/CT (and CD instrumentation, image reconstruction and data transfer for radiotherapy planning. Radiother Oncol 2010;96:288-97.
39. Thorwarth D, Beyer T, Boellaard R, de Ruysscher D, Grgic A, Lee JA et al. Technical aspects and recommendations on methodological approaches towards the integration of FDG-PET/CT into external beam Radiation Therapy Treatment Planning. Nuklearmedizin 2012;51:140-53.
40. Souvatzoglou M, Bengel F, Busch R, Kruschke C, Fernolendt H, Lee D et al. Attenuation correction in cardiac PET/CT with three different CT protocols: a comparison with conventional PET. Eur J Nucl Med Mol Imaging 2007;34:1991-2000. (Pubitemid 350212118)
41. Stergar H, Krause BJ, Eschmann SM, Juergens KU, Kuehl H, Pfannenberg AC et al. Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter study. Nuklearmedizin 2010;49:129-37.
42. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol 2008;47:1201-10.
43. Christian N, Lee JA, Bol A, De Bast M, Jordan B, Grégoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009;91:101-6.
44. Bussink J. Quantification of tumour hypoxia. Functional histology and autoradiography. Nuklearmedizin 2010;49(Suppl 1):S37-40.
45. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol 2010;96:302-7.
46. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010;97:172-5.
47. Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42. (Pubitemid 350251048)
48. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54:201-7.
49. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2013;40:186-97.
50. Durand RE, Aquino-Parsons C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemoradiation. Radiother Oncol 2006;80:138-42. (Pubitemid 44314017)
51. Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 2004;64:6183-9. (Pubitemid 39129420)
52. 18F]Fluoromisonidazole PET imaging. Phys Med Biol 2012;57:1675-84.
53. 18F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers. Radiother Oncol 2011;99:412-7.
54. Wang K, Yorke E, Nehmeh SA, Humm JL, Ling CC. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys 2009;36:4400-8.
55. Bayer C, Shi K, Astner ST, Maftei CA, Vaupel P. Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 2011;80:965-8.
56. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011;25:625-33.
57. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41. (Pubitemid 44497258)
58. Busk M, Munk OL, Jakobsen S, Wang T, Skals M, Steiniche T et al. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol 2010;49:922-33.
59. Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD et al. Image-guided P02 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J Nucl Med 2012;53:1608-15.
60. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol 2009;54:3083-99.
61. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209-24. (Pubitemid 40767811)
62. Casciari JJ, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys 1995;22:1127-39.
63. Guo H, Renaut RA, Chen K. An input function estimation method for FDG-PET human brain studies. Nucl Med Biol 2007;34:483-92. (Pubitemid 46963013)
64. Kudomi N, Bucci M, Oikonen V, Silvennoinen M, Kainulainen H, Nuutila P et al. Extraction of input function from rat [18F]FDG PET images. Mol Imaging Biol 2011;13:1241-9.
65. 215O PET imaging of rat heart and a blood flow-through detector. Mol Imaging Biol 2012;14:509-16.
66. Ljungkvist ASE, Bussink J, Kaanders JHAM, Rijken PF, Begg AC, Raleigh JA et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005;62:1157-68. (Pubitemid 40884431)
67. Casciari JJ, Sotirchos SV, Sutherland RM. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J Cell Physiol 1992;151:386-94.
68. Monnich D, Troost EGC, Kaanders JHAM et al. Correlations between tumor oxygenation and 18F-Fluoromisonidazole PET data simulated based on microvasculature images. Acta Oncol 2013 [In press]. Ref 68: doi: 10.3109/0284186X.2013.812796
69. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A et al. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia 2009;11:247-59.
70. Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjaer A, Engelholm SA. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 2012;102:424-8.
71. Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R. Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol 2012;105:36-40.
72. Thorwarth D, Leibfarth S, Mönnich D. Potential role of PET/MRI in radiotherapy treatment planning. Clinical and Translational Imaging 2013;1:45-51.
73. Leibfarth S, Monnich D, Siegel C et al. Deformable multimodal image registration strategies for the integration of PER/MR data into radiotherapy treatment planning. Acta Oncol 2013 [In press]. Ref 73: doi: 10.3109/0284186X.2013.813964
74. Castadot P, Geets X, Lee JA, Christian N, Gregoire V. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. Radiother Oncol 2010;95:209-17.
75. Lian J, Xing L, Hunjan S, Dumoulin C, Levin J, Lo A et al. Mapping of the prostate to endorectal coil-based MRI/MRSI and CT: a deformable registration and validation study. Med Phys 2004;31:3087-94. (Pubitemid 39552699)
76. Sohn M, Birkner M, Chi Y, Wang J, Di Y, Berger B, Alber M. Model-independent, multimodality deformable image registration by local matching of anatomical features and minimization of elastic energy. Med Phys 2008;35:866-78. (Pubitemid 351322668)
77. Dmitriev ID, Loo CE, Vogel WV, Pengel KE, Gilhuijs KGA. Fully automated deformable registration of breast DCE-MRI and PET/CT. Phys Med Biol 2013;58:1221-33.